Ceribell, Inc.
About Ceribell, Inc.
CeriBell Inc is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable, and rapidly deployable hardware with sophisticated artificial intelligence (AI)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. Its products are Point-of-Care EEG, Clarity, and EEG Portal.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $89.1M
- Net income
- -$53.4M
- Total assets
- $195.8M
- Market cap
- $692.5M
- Gross margin
- 87.9%
- Operating margin
- -65.6%
- Net margin
- -60.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $89.1M
- Cost of revenue
- $10.8M
- Gross profit
- $78.3M
- Operating expenses
- $136.7M
- Operating income
- -$58.4M
- Income tax
- $0
- Net income
- -$53.4M
- EPS (basic)
- $-1.46
- EPS (diluted)
- $-1.46
Balance sheet
- Total assets
- $195.8M
- Current assets
- $186.7M
- Total liabilities
- $40.5M
- Current liabilities
- $19.2M
- Shareholders’ equity
- $155.3M
Cash flow
- Operating cash flow
- -$40.8M
- Investing cash flow
- -$118.1M
- Financing cash flow
- $5.1M
- Net cash flow
- -$153.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $692.5M
- EPS (diluted)
- $-1.46
- Shares outstanding
- 38.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 11, 2024
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $53.4M in FY2025.
- Revenue grew 36% from FY2024 to FY2025.
- Gross margin of 87.9%, net margin -60.0%.
- Trading 23% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Ceribell, Inc..
Write a review
News about Ceribell, Inc.
News & sentiment via Polygon.io
